.jpg)
- Jan 23
Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
23 Jan 2024: Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted...
- Jul 21, 2023
Aravax appoints Annette Leahy as Director of Clinical Operations
21 July 2023, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
- May 31, 2023
Aravax doses first patient in Phase 2 peanut allergy clinical trials
1 June, Melbourne, Australia: The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax,...
- Mar 7, 2023
Aravax initiates Phase 2 peanut allergy clinical trials in Australia
8 March 2023, Melbourne, Australia: Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are...
- Dec 19, 2022
Aravax commences Phase 2 in peanut allergy with $20m Series B from Brandon Capital and Tenmile
20 December 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company developing the first safe, convenient, and...
- May 5, 2022
Aravax appoints Dr Brett Haumann to Board of Directors
06 May 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy...